Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2023)

Silence Therapeutics' Total Non-Current Liabilities history spans 5 years, with the latest figure at $73.2 million for Q4 2023.

  • For Q4 2023, Total Non-Current Liabilities fell 1.65% year-over-year to $73.2 million; the TTM value through Dec 2023 reached $73.2 million, down 1.65%, while the annual FY2023 figure was $73.4 million, 6.59% down from the prior year.
  • Total Non-Current Liabilities for Q4 2023 was $73.2 million at Silence Therapeutics, down from $74.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $97.7 million in Q4 2021 and bottomed at $19.9 million in Q4 2019.
  • The 5-year median for Total Non-Current Liabilities is $73.2 million (2023), against an average of $66.6 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 239.82% in 2020 before it decreased 23.81% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $19.9 million in 2019, then soared by 239.82% to $67.8 million in 2020, then surged by 44.17% to $97.7 million in 2021, then dropped by 23.81% to $74.5 million in 2022, then dropped by 1.65% to $73.2 million in 2023.
  • Per Business Quant, the three most recent readings for SLN's Total Non-Current Liabilities are $73.2 million (Q4 2023), $74.5 million (Q4 2022), and $97.7 million (Q4 2021).